Replimune’s (REPL) investment thesis changed dramatically this week after the FDA rejected its lead cancer therapy, RP1, for a second time, sending shares down approximately 64% and forcing management into cost-cutting mode.

The market is now questioning whether RP1 can still win approval and whether Replimune has enough capital to withstand a prolonged setback if the FDA requires more than manufacturing fixes.

With RP1 representing the company’s primary source of value, Replimune’s future may depend on whether management can quickly repair its regulatory path before financing pressure becomes unavoidable.

Second Replimune FDA rejection resets biotech company’s thesis

Replimune is a clinical-stage biotech company focused on developing cancer immunotherapies, and RP1 is its lead drug candidate.

Because the company has no approved products or meaningful revenue, much of Replimune’s valuation has been tied to investor expectations that RP1 would eventually reach commercialization.

The FDA issued Replimune a second Complete Response Letter for RP1 on Friday, April 10, rejecting the company’s resubmitted biologics license application for RP1 in combination with Bristol Myers Squibb’s nivolumab in advanced unresectable cutaneous melanoma following prior anti-PD-1 treatment.

CEO Sushil Patel said the company is “deeply disappointed” and will work urgently with the FDA, but “at this point we have no choice but to eliminate jobs, including substantially scaling back our U.S.-based manufacturing operations.”

More Collapses:

  • Key auto parts and services company files Chapter 11 bankruptcy
  • Key travel brand files for Chapter 11 bankruptcy
  • Self-driving-car company files for Chapter 11 bankruptcy protection

Replimune said the CRL was related “solely to manufacturing issues at a third-party facility.” However, analyst commentary following the decision suggested the underlying concerns may run deeper, specifically whether the filing demonstrated sufficient efficacy and whether its response assessment methods met FDA standards.

That distinction is central to the investment case. A manufacturing-related CRL may delay commercialization and increase remediation costs, but it typically preserves the broader thesis. An efficacy- or methodology-driven CRL raises a more serious question: whether RP1 can be approved on the current data package at all.

BMO said Replimune and the FDA were “not truly aligned” on the use of a single-arm trial to support the filing, while Wedbush pointed to unresolved concerns around response criteria versus RECIST v1.1.

Wall Street questions Replimune’s confirmatory path

Perhaps most concerning, Wall Street now questions whether IGNYTE-3, Replimune’s ongoing Phase 3 trial designed to support eventual RP1 approval, will be enough to satisfy the FDA.

That marks a significant shift in investor perception. After the first rejection in July 2025, BioPharma Dive noted, IGNYTE-3 was largely viewed as the pathway to de-risk RP1 and support eventual approval. Now the market is questioning whether the confirmatory trial is even capable of resolving the FDA’s concerns.

BMO cut its price target to $1 and cited concerns. “The letter makes clear that while FDA allowed Replimune to resubmit their BLA, the company and FDA were never truly in alignment on either the use of a single arm trial (RPL-001-16) for their initial BLA submission or the methods Replimune had used to assess efficacy in the trial.”

Following the CRL, JPMorgan said the decision “raises continued questions on whether data from the ongoing pivotal IGNYTE-3 trial will be sufficient from the FDA’s perspective.” Wedbush argued that the FDA did not believe that IGNYTE’s exploratory analyses and early Phase 3 data resolved prior concerns about inconsistent response criteria relative to RECIST v1.1.

That pressure also affects the rest of the pipeline. Programs such as RP2 and RPL-002 currently do not appear large enough to offset a major impairment in RP1’s value.

Wall Street now fears Replimune’s Phase 3 IGNYTE-3 trial may not be enough to resolve FDA concerns and secure RP1 approval.

ingwervanille via Getty Images

Replimune shares crash as financing risk rises

Prior to the rejection, Replimune had $269.1 million in cash and equivalents at the end of 2025, with management expecting this cash to fund the business through the first quarter of calendar year 2028.

A longer regulatory path means more cash burn, while removing the near-term launch catalyst that could have supported a stronger valuation and more favorable financing options. With shares near $1.70, any equity raise would likely be highly dilutive. Traditional debt financing is also difficult for a clinical-stage biotech with no revenue base.

Management’s response reinforced that reality. Replimune shared plans to reduce headcount and scale back U.S. manufacturing operations, a move CEO Sushil Patel said reflects the company’s need to adjust after the FDA setback.

Right now, it appears as though management is focused on preserving capital and extending its runway while reassessing the regulatory path forward. Financing risk is now a major part of the investment thesis.

Key takeaways for Replimune investors

Replimune is still alive, but the company’s margin for error has narrowed significantly.

A single FDA rejection can often be overcome, especially if the issue is operational or manufacturing-related. But a second rejection, combined with analyst concerns that the FDA may be questioning RP1’s efficacy package and trial design, creates a much more serious problem.

At this point, Replimune is being valued like a biotech company fighting to salvage its lead program before cash burn and financing pressure force difficult decisions.

If management can realign with the FDA and prove RP1 remains approvable, the stock could recover meaningfully from current levels. If not, investors may need to prepare for a long and uncertain road ahead.

Related: No drug has ever cured osteoarthritis. This biotech believes they’ve made one.